Komori
Fuso Pharmaceutical Industries (4538) · PolicyUpdated cumulative third-quarter impact of adoption

Application of the Accounting Standard for Revenue Recognition

First written in FY2022-Q1. . Latest entry: FY2022-Q3.

3entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2022-Q1 – FY2022-Q32021: 220212022: 12022
Same theme, other companies

4 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 33 companies compared. The sentences above are computed from all 33.
Full recordFilings, disclosures and news, newest first
  1. FY2022-Q3Updated cumulative third-quarter impact of adoptionAnnual report

    「As a result, revenue for the cumulative period of the third quarter of the current fiscal year decreased by ¥667 million and cost of sales decreased by ¥663 million, resulting in decreases of ¥3 million each in operating income, ordinary income and profit before income taxes for the quarter. The balance of retained earnings at the beginning of the fiscal year also decreased by ¥40 million.」

    As the impact of applying the revenue recognition accounting standard for the cumulative period of the third quarter, revenue decreased by ¥667 million, cost of sales decreased by ¥663 million, and operating income, ordinary income and profit before income taxes each decreased by ¥3 million.
  2. FY2022-Q2Updated the impact of application for the cumulative period of the second quarterAnnual report

    「As a result, revenue for the cumulative period of the second quarter of the current fiscal year decreased by ¥430 million and cost of sales decreased by ¥428 million, resulting in decreases of ¥1 million each in operating income, ordinary income and profit before income taxes for the quarter. The balance of retained earnings at the beginning of the fiscal year also decreased by ¥40 million.」

    Regarding application of the revenue recognition accounting standard, the Company disclosed that revenue for the cumulative period of the second quarter decreased by ¥430 million, cost of sales decreased by ¥428 million, operating income, ordinary income and profit before income taxes for the quarter each decreased by ¥1 million, and retained earnings at the beginning of the fiscal year decreased by ¥40 million.
  3. FY2022-Q1First statedAnnual report

    「The Company applied the Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, 31 March 2020) and other relevant standards from the beginning of the first-quarter accounting period of the current fiscal year, and recognizes revenue at the amount expected to be received in exchange for the promised goods or services when control of those goods or services is transferred to the customer. As a result, revenue for the cumulative period of the first quarter of the current fiscal year decreased by ¥227 million and cost of sales decreased by ¥225 million, resulting in decreases of ¥1 million each in operating income, ordinary income and profit before income taxes for the quarter. The balance of retained earnings at the beginning of the fiscal year also decreased by ¥40 million.」

    The Company applied the revenue recognition accounting standard and other relevant standards from the beginning of the first-quarter accounting period of FY2022. The revenue recognition method was changed, resulting in decreases of ¥227 million in revenue and ¥225 million in cost of sales during the cumulative period of the first quarter of the current fiscal year, decreases of ¥1 million each in operating income, ordinary income and profit before income taxes for the quarter, and a ¥40 million decrease in retained earnings at the beginning of the fiscal year.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Fuso Pharmaceutical Industries yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Application of the Accounting Standard for Revenue Recognition | Fuso Pharmaceutical Industries,Ltd. (4538) | Komori